Agile Therapeutics (NASDAQ:AGRX) received a $8.00 price objective from analysts at HC Wainwright in a research report issued to clients and investors on Friday, December 22nd. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 143.90% from the stock’s previous close.
The analysts wrote, “it as Just Another Delay; Reiterate Buy but Lower to $8 Stock Data 12/21/2017 Price $4.76 Exchange NASDAQ Price Target $8.00 52-Week High $6.62 52-Week Low $2.04 Enterprise Value (M) $131.3 Market Cap (M) $163 Shares Outstanding (M) 34.2 3 Month Avg Volume 267,948 Short Interest (M) 0.30 Balance Sheet Metrics Cash (M) $43.8 Total Debt (M) $12.1 Total Cash/Share $1.28 EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.27) (0.26)A (0.28) 2Q (0.29) (0.26)A (0.26) 3Q (0.27) (0.22)A (0.29) 4Q (0.18) (0.24) (0.32) FY (1.02) (0.98) (1.16) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 0.0 0.0A 0.0 2Q 0.0 0.0A 0.0 3Q 0.0 0.0A 0.0 4Q 0.0 0.0 0.0 FY 0.0 0.0 0.0 7 6 5 4 3 2 1 DEC- 16 APR- 17 AUG- 17 DEC- 17 20 15 10 5 0 Vol. (mil) Price Twirla Complete Response Letter surprisingly focused on patch adhesion; we believe the issues are readily addressable. The consensus investor Twirla sticking issue has been around the “high” Phase 3 Pearl Index (implied lower efficacy) vs. prior.””
Other research analysts also recently issued research reports about the stock. Royal Bank of Canada reissued a “buy” rating and set a $10.00 target price on shares of Agile Therapeutics in a research report on Wednesday, October 18th. ValuEngine cut shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Janney Montgomery Scott restated a “buy” rating and issued a $13.00 price target (down from $15.00) on shares of Agile Therapeutics in a report on Thursday, August 24th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 price target on shares of Agile Therapeutics in a report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $9.20.
Shares of Agile Therapeutics (AGRX) opened at $3.28 on Friday. Agile Therapeutics has a 12 month low of $1.93 and a 12 month high of $5.60. The firm has a market cap of $110.08, a price-to-earnings ratio of -3.57 and a beta of 2.01. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.14.
Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.03. sell-side analysts expect that Agile Therapeutics will post -0.97 EPS for the current year.
Several large investors have recently bought and sold shares of AGRX. Janney Montgomery Scott LLC purchased a new position in shares of Agile Therapeutics during the 2nd quarter valued at approximately $122,000. Royce & Associates LP increased its holdings in shares of Agile Therapeutics by 1.1% during the 2nd quarter. Royce & Associates LP now owns 998,582 shares of the specialty pharmaceutical company’s stock valued at $3,745,000 after purchasing an additional 11,000 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Agile Therapeutics by 39.2% during the 2nd quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after purchasing an additional 780,578 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Agile Therapeutics by 604.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock worth $359,000 after acquiring an additional 82,213 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in Agile Therapeutics in the 2nd quarter worth $309,000. 72.92% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “HC Wainwright Reiterates $8.00 Price Target for Agile Therapeutics (NASDAQ:AGRX)” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.thelincolnianonline.com/2018/01/14/hc-wainwright-analysts-give-agile-therapeutics-agrx-a-8-00-price-target-3-updated-updated-updated.html.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.